These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10353890)

  • 41. Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis.
    Keiser PB; Miller LB; Biggs-Cicatelli S; Zollinger WD
    Vaccine; 2009 Nov; 27(49):6809-13. PubMed ID: 19761833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The new Norwegian meningococcal vaccine].
    Bjune G
    Tidsskr Nor Laegeforen; 1987 Nov; 107(32):2868-9. PubMed ID: 3122361
    [No Abstract]   [Full Text] [Related]  

  • 43. [Evaluation of the immunological activity and safety of group B meningococcal vaccine prepared from a natural complex of specific polysaccharide and outer membrane proteins].
    Kuvakina VI; Golovina LI; Mishina AI; Skirda TA; Bobyleva GV; Mikheeva NG; Chernyshova TF; Temper RM; Ermolenko ZN
    Zh Mikrobiol Epidemiol Immunobiol; 2002; (2):33-7. PubMed ID: 12043150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B.
    Pillai S; Howell A; Alexander K; Bentley BE; Jiang HQ; Ambrose K; Zhu D; Zlotnick G
    Vaccine; 2005 Mar; 23(17-18):2206-9. PubMed ID: 15755596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease.
    Zollinger WD; Boslego J; Moran E; Garcia J; Cruz C; Ruiz S; Brandt B; Martinez M; Arthur J; Underwood P
    NIPH Ann; 1991 Dec; 14(2):211-2; discussion 213. PubMed ID: 1812433
    [No Abstract]   [Full Text] [Related]  

  • 46. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
    Frasch CE; Borrow R; Donnelly J
    Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The prospects for a study of meningococcal infection caused by serogroup B today].
    Demina AA
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Dec; (12):111-7. PubMed ID: 3149839
    [No Abstract]   [Full Text] [Related]  

  • 49. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines.
    Heyderman RS; Davenport V; Williams NA
    Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anti-meningococcal vaccines].
    Taha MK; Alonso JM
    Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in the development of vaccines against Neisseria meningitidis.
    Tan LK; Carlone GM; Borrow R
    N Engl J Med; 2010 Apr; 362(16):1511-20. PubMed ID: 20410516
    [No Abstract]   [Full Text] [Related]  

  • 53. Meningococcal meningitis.
    Lancet; 1989 Mar; 1(8639):647-8. PubMed ID: 2564462
    [No Abstract]   [Full Text] [Related]  

  • 54. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Borrow R; Balmer P; Miller E
    Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On the neisserial vaccine quest: Neisseria Vaccines 2007.
    Pajón R; Niebla O; Yero D; Pérez O; Cabrera O; Findlow J; Balmer P; Borrow R
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):545-50. PubMed ID: 17678419
    [No Abstract]   [Full Text] [Related]  

  • 56. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. For discussion: live attenuated vaccines for group B meningococcus.
    Tang C; Moxon R; Levine MM
    Vaccine; 1999 Jan; 17(2):114-7. PubMed ID: 9987144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The meningococcal serogroup B vaccine protection trial in Norway 1988-1991: trial surveillance by an independent group.
    Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):135-6; discussion 136-7. PubMed ID: 1812427
    [No Abstract]   [Full Text] [Related]  

  • 60. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).
    Martínez AI; Dominguez A; Oviedo M; Minguell S; Jansa JM; Codina G; Vazquez JA;
    Vaccine; 2009 May; 27(25-26):3496-8. PubMed ID: 19200816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.